Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.
As of 18 November 2026, for the company name Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 23 active records with this name as holder; 13 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
28 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Dapoxetine Hydrochloride Tablets 2 records · Latest accepted 2024/08/13
Generic · 2
Temozolomide For Injection 3 records · Latest accepted 2023/11/29
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302623 | Supplement | 2023/11/29 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2302577 | Supplement | 2023/11/22 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2301699 | Supplement | 2023/07/29 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
Sildenafil Citrate Tablets 3 records · Latest accepted 2023/07/26
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301992 | Generic | 2023/07/26 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2201973 | Generic | 2022/11/14 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2201972 | Generic | 2022/11/14 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Avanafil Tablets 3 records · Latest accepted 2023/07/11
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2301538 | Supplement | 2023/07/11 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2301537 | Supplement | 2023/07/11 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2301536 | Supplement | 2023/07/11 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 4 records · Latest accepted 2023/05/17
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301339 | Generic | 2023/05/17 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2301338 | Generic | 2023/05/17 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2301337 | Generic | 2023/05/17 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2301336 | Generic | 2023/05/17 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Tadalafil Tablets 3 records · Latest accepted 2023/04/28
Supplement · 1Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2300923 | Supplement | 2023/04/28 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2102033 | Generic | 2021/11/19 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2101582 | Generic | 2021/08/16 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Sivelestat Sodium for Injection 2 records · Latest accepted 2023/04/11
New drug · 1Supplement · 1
Azilsartan and Amlodipine Tablets 1 records · Latest accepted 2022/08/17
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2200066 | Generic | 2022/08/17 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Sugammadex Sodium Injection 2 records · Latest accepted 2022/08/01
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201201 | Generic | 2022/08/01 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., Ltd | CDE ↗ |
| CYHS2201200 | Generic | 2022/08/01 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., Ltd | CDE ↗ |
Esomeprazole Sodium for Injection 2 records · Latest accepted 2022/06/29
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2201057 | Supplement | 2022/06/29 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2201056 | Supplement | 2022/06/29 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Tenofovir Disoproxil Fumarate Tablets 1 records · Latest accepted 2021/11/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2102178 | Supplement | 2021/11/25 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
Levoleucovorin for Injection 2 records · Latest accepted 2021/05/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2101018 | Supplement | 2021/05/06 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Di Yi Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CXHB2101017 | Supplement | 2021/05/06 | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Di Yi Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
23 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Dapoxetine Hydrochloride Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20256001 | 2025/11/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20256000 | 2025/11/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20244459 | 2024/07/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sugammadex Sodium Injection | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., Ltd | 国药准字H20243562 | 2024/04/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20243514 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20243513 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20247036 | 2024/02/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20233235 | 2023/02/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20233240 | 2023/02/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Esomeprazole Sodium for Injection | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | 国药准字H20203096 | 2022/03/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Esomeprazole Sodium for Injection | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | 国药准字H20227040 | 2022/03/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Temozolomide For Injection | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Sichuan Huiyu Pharmaceutical Co., Ltd. | 国药准字H20213724 | 2021/09/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Silodosin Capsules | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20213612 | 2021/07/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Azacitidine For Injection | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20213493 | 2021/06/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dienogest Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Nanjing Bai Jing Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20213439 | 2021/06/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20213338 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20213337 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20213336 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20203740 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20203739 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20203738 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tenofovir Disoproxil Fumarate Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20193433 | 2019/12/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ticagrelor Tablets | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | 国药准字H20193252 | 2019/09/05 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
13 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 瑞卢戈利 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20260000272 | I | 2026/04/22 | CDE ↗ |
| 枸橼酸西地那非 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20240000285 | A | 2025/07/31 | CDE ↗ |
| JC242 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20240000042 | I | 2024/01/29 | CDE ↗ |
| 舒更葡糖钠 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20220000464 | A | 2026/01/06 | CDE ↗ |
| 赛洛多辛 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20200000376 | A | 2026/10/21 | CDE ↗ |
| HTMC0435 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20190001126 | I | 2019/12/16 | CDE ↗ |
| 西维来司他钠 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20190001060 | A | 2026/10/21 | CDE ↗ |
| 富马酸替诺福韦二吡呋酯 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20190006796 | A | 2023/03/24 | CDE ↗ |
| 阿伐那非 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20190000743 | A | 2025/12/03 | CDE ↗ |
| 替莫唑胺 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20180001446 | A | 2026/05/22 | CDE ↗ |
| 阿扎胞苷 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20180000608 | A | 2026/04/04 | CDE ↗ |
| 左亚叶酸 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20180001732 | A | 2026/03/21 | CDE ↗ |
| 艾司奥美拉唑钠 · No verified English name | Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | Y20170001052 | A | 2023/11/23 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
9 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Relugolix Tablets | CYHS2601163 | Generic | 2026/05/18 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| 恩格列净二甲双胍缓释片(III) · No verified English name | CYHB2500494 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| 恩格列净二甲双胍缓释片(II) · No verified English name | CYHB2500493 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| 恩格列净二甲双胍缓释片(I) · No verified English name | CYHB2500492 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| Azilsartan and Amlodipine Tablets | CYHS2402787 | Generic | 2024/08/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| Metformin Hydrochloride And Empagliflozin Extended Release Tablets | CYHB2401229 | Supplement | 2024/08/09 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| Avanafil Tablets | CYHB2202295 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| Avanafil Tablets | CYHB2202294 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
| Avanafil Tablets | CYHB2202293 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.